Press Releases<< Back
CHF Solutions Sponsored AATS Session on Post-Cardiac Surgery, Highlighting Benefits of Using the Aquadex FlexFlow® System Following Cardiac Surgery
The panel, titled “Personalized Medicine: Improving Clinical Outcomes with Novel Fluid Management Strategies,” highlighted a discussion on the use of the Aquadex FlexFlow system to help manage risks associated with fluid overload in adult cardiac surgery patients. Among the key reasons cited for using the device were the ease of use for both doctors and other hospital staff, rapid patient recovery, decrease in mortality, efficient utilization of hospital resources, and the ability to personalize treatment based on the individual patient’s need. The panel included
“We continue to believe that utilizing ultrafiltration in post-cardiovascular surgery provides medical personnel with an important solution to treat fluid overload. The panel highlighted that the Aquadex FlexFlow system provided a gentler methodology that conformed to the physiology of each patient. We believe that this personalized approach contributes both to the patient’s recovery and the optimal utilization of hospital resources because many patients spend less time in the intensive care unit and only patients with urgent issues are receiving additional services, rather than those patients who were simply experiencing fluid overload,” said
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the effectiveness of the Aquadex FlexFlow system in treating patients following cardiac surgery. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
Chief Financial Officer
JQA Partners, Inc.
Source: CHF Solutions, Inc.